Alterity Therapeutics Data Presentations Support Advancement of ATH434 into
Phase 3 in Multiple System Atrophy
- Alterity's novel imaging and biomarker approach positions the Company at the forefront of
clinical research in MSA -
- End-of-Phase 2 FDA Meeting on track for mid-2026 to confirm path forward for Phase 3 -
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 19 May 2026: Alterity Therapeutics (ASX:
ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to
developing disease modifying treatments for neurodegenerative diseases, today announced that
presentations related to the Company's development program in Multiple System Atrophy (MSA)
were delivered at three medical conferences showcasing Alterity's novel imaging and biomarker
approach, promising Phase 2 data, and current plans to advance ATH434 into Phase 3 clinical
development.
"These data continue to strengthen the evidence that ATH434 has the potential to be the first
disease-modifying treatment for MSA, a rare and devastating disease with no approved therapy,"
said David Stamler, M.D., CEO of Alterity Therapeutics. "Our Phase 2 trial showed statistically
significant slowing of disease progression, and the use of advanced MRI methods gives us a
powerful way to identify the right patients and measure how the drug is working. Together, these
advances directly inform the design of our upcoming Phase 3 trial. By moving beyond traditional
trial paradigms, we are focused on identifying and treating the right patients with greater
precision, with the ultimate goal of delivering a meaningful therapeutic option for this
devastating disease."
Presentation Highlights:
Quantitative Susceptibility Mapping Detects Progressive Iron Accumulation in Early MSA
• Author: Oral presentation delivered by Paula Trujillo, PhD, Research Assistant Professor,
Department of Neurology, Vanderbilt University Medical Center
• Conference: The International Society for Magnetic Resonance in Medicine 2026 ISMRM and
ISMRT Annual Meeting and Exhibition
• Summary: New research shows that Alterity's MRI imaging approach can detect MSA in its
earliest stages and track brain iron changes over time, a methodology that could transform
how MSA trials are run. Dr. Trujillo presented findings recently published in NeuroImage
demonstrating that quantitative susceptibility mapping (QSM) detects progressive iron
Phase 3 in Multiple System Atrophy
- Alterity's novel imaging and biomarker approach positions the Company at the forefront of
clinical research in MSA -
- End-of-Phase 2 FDA Meeting on track for mid-2026 to confirm path forward for Phase 3 -
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA - 19 May 2026: Alterity Therapeutics (ASX:
ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to
developing disease modifying treatments for neurodegenerative diseases, today announced that
presentations related to the Company's development program in Multiple System Atrophy (MSA)
were delivered at three medical conferences showcasing Alterity's novel imaging and biomarker
approach, promising Phase 2 data, and current plans to advance ATH434 into Phase 3 clinical
development.
"These data continue to strengthen the evidence that ATH434 has the potential to be the first
disease-modifying treatment for MSA, a rare and devastating disease with no approved therapy,"
said David Stamler, M.D., CEO of Alterity Therapeutics. "Our Phase 2 trial showed statistically
significant slowing of disease progression, and the use of advanced MRI methods gives us a
powerful way to identify the right patients and measure how the drug is working. Together, these
advances directly inform the design of our upcoming Phase 3 trial. By moving beyond traditional
trial paradigms, we are focused on identifying and treating the right patients with greater
precision, with the ultimate goal of delivering a meaningful therapeutic option for this
devastating disease."
Presentation Highlights:
Quantitative Susceptibility Mapping Detects Progressive Iron Accumulation in Early MSA
• Author: Oral presentation delivered by Paula Trujillo, PhD, Research Assistant Professor,
Department of Neurology, Vanderbilt University Medical Center
• Conference: The International Society for Magnetic Resonance in Medicine 2026 ISMRM and
ISMRT Annual Meeting and Exhibition
• Summary: New research shows that Alterity's MRI imaging approach can detect MSA in its
earliest stages and track brain iron changes over time, a methodology that could transform
how MSA trials are run. Dr. Trujillo presented findings recently published in NeuroImage
demonstrating that quantitative susceptibility mapping (QSM) detects progressive iron